| | Staff Scientists and Clinicians
| Carlos A. Zarate, M.D. |
 |
|
Carlos A. Zarate, M.D. is Chief Experimental Therapeutics of the Mood and Anxiety Disorders Program at the National Institute of Mental Health, and Clinical Professor of Psychiatry and Behavioral Sciences, George Washington University
Dr. Zarate completed a Fellowship in Clinical Psychopharmacology at McLean Hospital from 1992-1993, after which he remained as a staff member until 1998. At McLean Hospital of the Consolidated Department of Psychiatry, Harvard Medical School, Dr. Zarate was the Director of the Bipolar and Psychotic Disorders Outpatient Services, Chair of the Pharmacy and Therapeutic Committee, and Director of the New and Experimental Clinic. From 1998 to 2000 Dr. Zarate was the Chief of the Bipolar and Psychotic Disorders Program, Associate Professor of Psychiatry and Chair of the Grand Rounds Committee at the University of Massachusetts Medical School. In January 2001, he joined the Mood and Anxiety Disorders Program at the National Institute of Mental Health.
His achievements and awards include the Ethel-DuPont Warren Award and Livingston Awards, Consolidated Department of Psychiatry, Harvard Medical School; Outstanding Psychiatrist Research Award, Massachusetts Psychiatric Association; Program for Minority Research Training in Psychiatry, American Psychiatric Association; National Institute of Health-National Institute of Mental Health Travel Award, 1994; American College of Neuropsychopharmacology Travel Awards 1994 and 1995; the National Alliance for Research on Schizophrenia and Depression Young Investigator Award, 1996-1998; The Diversity and Advocacy Award, Hispanic Research Initiative Committee, NIMH, 2002; the mentor of the year, intramural program NIMH 2004; the supervisor of the year NIMH; the National Alliance for Research on Schizophrenia and Depression Independent investigator award, 2005; and the National Institute of Health Director’s Award-Scientific/Medical in 2006.
|
| Research Interests |
| He has published extensively on the pathophysiology and treatment of major depressive disorders and bipolar disorder. His research interests include the investigation of the pathophysiology of mood disorders and the development of novel therapeutics for patients with mood disorders.
|
| Representative Selected Recent Publications: |
- Zarate CA Jr, Singh JB, Carlson PJ, Quiroz J, Jolkovsky L, Luckenbaugh DA, Manji HK: Efficacy of a Protein Kinase C Inhibitor (Tamoxifen) in the Treatment of Acute Mania: A Pilot Study. Bipolar Disorders , 9:551-560, 2007.
- Maeng S, Zarate CA Jr, Du J, Schloesser R, McCammon J, Chen G, Manji HK: Cellular mechanism underlying the antidepressant effects of ketamine: role of AMPA receptors. Biol Psychiatry , Jul 20;, 2007.
- Zarate CA, Jr, Singh J, Carlson P, Brutsche N, Ameli R, Luckenbaugh D, Charney DS, Manji HK: A Randomized Trial of an NMDA Antagonist in Treatment-Resistant Major Depression. Arch Gen Psychiatry , 63:856-64, 2006.
- Zarate CA Jr, Singh J, Manji HK: Cellular plasticity cascades: targets for the development of novel therapeutics for Bipolar Disorder. Biol Psychiatry , 1;59:1006-20, 2006.
- Zarate CA Jr, Singh J, Quiroz, JA, Denicoff KD, De Jesus G, Luckenbaugh D, Manji HK, Charney DS: Memantine in major depression: a double-blind placebo-controlled study. Am J Psychiatry , 163:153-155, 2006.
- Zarate CA Jr, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, Charney D, Manji HK: An Open-Label Trial of Riluzole in Treatment-Resistant Major Depression. Am J Psychiatry , 161:171-174, 2004.
|
|
|
|
|
